Veterinary Medicines

CANIVAC LR Λυοφιλοποιημένο υλικό και διαλύτης για ενέσιμο εναιώρημα

Authorised
  • Leptospira interrogans, serogroup Grippotyphosa, serovar Grippotyphosa, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Rabies virus, Inactivated
Download as PDF

Product identification

Medicine name:
CANIVAC LR Λυοφιλοποιημένο υλικό και διαλύτης για ενέσιμο εναιώρημα
Active substance:
  • Leptospira interrogans, serogroup Grippotyphosa, serovar Grippotyphosa, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Rabies virus, Inactivated
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Grippotyphosa, serovar Grippotyphosa, Inactivated
    32.00
    log2 geometric mean titre
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, Inactivated
    32.00
    log2 geometric mean titre
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain 16069, Inactivated
    32.00
    log2 geometric mean titre
    /
    1.00
    Dose
  • Rabies virus, Inactivated
    2.00
    international unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
      • Not applicable
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Candilidis S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 95611/19.10.2021/19-01-2022/K-0250101
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 10/08/2023
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 10/08/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."